Company / PP&E (Net)
Anika Therapeutics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$40.3M
FY2025
5-year range
$37.4M / $48.3M
FY2021-FY2025
Trend
+3.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 10 years, ranging from $37M in FY2023 to $56M in FY2017.
Based on SEC 10-K filings.
$40M in FY2025 with a 5-year CAGR of -4.5%.
Improved from $37M to $40M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -5.8%
- 5-Year CAGR
- -4.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -4.5%, indicating a declining trend.
- In FY2025, pp&e (net) increased 3.4% year-over-year.
- Peak pp&e (net) was recorded in FY2017.
- Lowest pp&e (net) in the period was in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.3M | +3.4% |
| FY2024 | $39.0M | +4.1% |
| FY2023 | $37.4M | -22.4% |
| FY2022 | $48.3M | +1.4% |
| FY2021 | $47.6M | -6.3% |
| FY2020 | $50.8M | +0.0% |
| FY2019 | $50.8M | -6.2% |
| FY2018 | $54.1M | -3.7% |
| FY2017 | $56.2M | +7.4% |
| FY2016 | $52.3M | +30.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026